Neuronity

Neuronity is a biotech startup founded in 2022, with a clear mission of transforming the treatment of neurodegenerative diseases. Their slogan "Transforming neurodegenerative disease treatments with innovative immune therapies" echoes their dedication to this cause. The company focuses on age-related neurological disorders like Parkinson's disease, leveraging cutting-edge gene and cell therapy. Their approach aims to restore healthy immune cell function in aging brains, targeting the root causes of these conditions to reduce unmet needs of patients, families, and caregivers. The most recent investment of $780.00K came in the form of a grant investment on 03 July 2023 from The Michael J. Fox Foundation for Parkinson's Research, showcasing the industry’s recognition of Neuronity’s potential impact. Their headquarters are situated in the United States, at the epicenter of biotech innovation. Neuronity’s vision extends beyond business, aiming to improve the quality of life for individuals affected by neurodegenerative diseases through strategic collaborations and groundbreaking interventions. Its commitment to this cause attracts attention from investors and stakeholders, positioning it at the forefront of CNS disease therapeutics. #Neuroscience #Biotech #GeneTherapy #CellTherapy #NeurodegenerativeDiseases